Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RESEARCH TOOLSreports
TransCode Therapeutics (RNAZ) Stock Price & Analysis
211 Followers
RNAZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $128.00
Previous Close$0.83
Volume45.85K
Average Volume (3M)1.28M
Market Cap
$5.49M
Enterprise Value$929.09K
Total Cash (Recent Filing)$4.90M
Total Debt (Recent Filing)$339.41K
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 12, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-205.92
Shares Outstanding6,622,053
10 Day Avg. Volume376,857
30 Day Avg. Volume1,279,909
Standard Deviation0.45
R-Squared0.00466
Alpha-0.10
Financial Highlights & Ratios
Price to Book (P/B)1.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$3.00Price Target Upside261.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
TransCode Therapeutics News
Bulls Say, Bears Say
Bulls Say
Combination Therapy PotentialTTX-MC138 has shown potential to be combined with other agents including doxorubicin and temozolomide (TMZ), and potential for combination with checkpoint inhibitors in future studies which may demonstrate synergistic efficacy.
Drug SafetyA microdose of TTX-MC138 continues to be safe with no adverse events of any kind observed.
Regulatory ApprovalTransCode announced that it has received FDA IND clearance for the Phase 1/2 study evaluating TTX-MC138 for treatment of advanced solid tumors.
Bears Say
Financing RequirementsThe company will need to secure additional funding to sustain operations for the remainder of 2024.
Market RisksRisks include safety signals, lower-than-expected efficacy, greater-than-expected commercial competition, regulatory concerns, financing requirements, microcap stock, low trading volume, and de-listing risk if shares go under $1.
Regulatory ConcernsThe threat of de-listing remains, prompting the company to gear up for an appeal against Nasdaq's recommendation.
---
Ownership Overview
3.57% Insiders
0.02% Mutual Funds
0.53% Other Institutional Investors
95.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $0.42 and its highest was $128.00 in the past 12 months.
What is TransCode Therapeutics’s market cap?
Currently, no data Available
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 20 days.
How were TransCode Therapeutics’s earnings last quarter?
Currently, no data Available
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -$0.58.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 6,622,053 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
---
TransCode Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (261.88% Upside)
$3.00 (261.88% Upside)
Blogger Sentiment
Bullish
RNAZ Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.18%
12-Months-Change
Fundamentals
Return on Equity
-784.63%
Trailing 12-Months
Asset Growth
30.41%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
---
RNAZ Stock 12 Month Forecast
Average Price Target
$3.00
▲(261.88% Upside)
Technical Analysis
Best Analysts Covering RNAZ
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-73.63%
assigned a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -73.63% per trade.
---